ADAM12 and colorectal carcinoma: The aims of the current study were to evaluate the role of ADAM12 in human CRC progression and prognosis and to elucidate whether targeted downregulation of ADAM12 could lead to therapeutic sensitization using an in vivo mouse xenograft model.